Drug and Therapeutics Committee – Minutes –approved

Date / Time	Thursday 9th February 2017
Venue	The Committee Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs Susan Greene, Senior Pharmacy Technician (SG) & Wendy Hornsby
Quorate: Yes / No	Yes
Attendance	Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services (SPG) Mr P O'Brien, Deputy Chief Pharmacist Dr A Sampson, Infectious Diseases Consultant Dr H Klonin, Consultant Paediatrician Mr K McCorry, Medicines Management, East Riding Dr O Ogunbambi, Consultant Rheumatologist Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Prof M Lind, Vice Chair, Professor of Oncology Dr F Umerah, Consultant Anaesthetist Mrs S Phillips, Lay Member
Apologies	Dr Roper, Chair, Hull CCG Caroline Grantham, Medicines Management Nurse, HEY

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2017.02.01	**Apologies**	As above. Mrs S Phillips was welcomed as the new D&T Committee Lay Member.					
2017.02.02	**Declarations of Interest**	None.					
2017.02.03	**Minutes of the previous meeting**	The minutes were accepted as a true record.					02/17
2017.02.04	**Action Tracker**	**NICE Guidance – July 16** TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa. “Dermatology” to be added to formulary.	 Action complete				 02/17
2017.02.04	**Action Tracker**	**NICE Guidance November 16** TA 417-Nivolumab for previously treated advance renal cell carcinoma – ML to request application. ML informed the committee that a new chairperson would be appointed to the chemotherapy committee and once in post the committee would look at all positive NICE TA’s requiring applications. **MHRA Drug Safety Update – October 2026** OO has discussed etoricoxib with Rheumatology colleagues. **Bisphosphonates as supportive therapy for Breast Cancer** ML had assessed the San Antonio Breast Cancer Symposium paper but felt that the data from this study was insufficient, as the difference between groups was not statistically significant.	 Action complete SG to send list of TA’s requiring applications to ML Action complete Action complete	 SG to prepare and send list	 SG	 03/17	 02/17 02/17 02/17

		POB has liaised with Leeds and was awaiting a reply about what they do.	Action complete				02/17
		Once Leeds replied, ML would write a local protocol - to be sent to HERPC for further discussion.	ML to write protocol	ML to send to SG for HERPC	ML	03/17	
		New Product Request Ferraccru (Ferric Maltol) - Dr S Sebastian ML has written to Dr Sebastian regarding follow up and stopping treatment and is awaiting a reply.	Action complete				02/17
		NICE Guidance TA420 Ticagrelor – Guideline had been reviewed regarding duration of treatment & sent to HERPC.	Action complete				02/17
		TA421/422/423/424 – ML had asked for new product applications.	Action complete				02/17
		Correspondence Received Management of High Output Stoma and Enterocutaneous Fistulae in Adults guideline was discussed at HERPC.	Action complete				02/17
2017.02.05	**New Product Requests**	**Mepolizumab – Dr M Crooks** Approved in line with NICE TA431, but NHSE have not yet commissioned, therefore awaiting this. Mepolizumab will be a red drug and require Blueteq entry, following regional MDT discussions.	Approved, in line with TA431 & future NHSE commissioning	AM to write applicants and SG will update formulary	AM/SG	03/17	
		Fluticasone furoate and vilanterol (Relvar Ellipta) – Dr S Faruqi Approved for patients with severe asthma who are on DOT, to determine if they improve on regular supervised treatment. Proposed as a red drug for HERPC and not for primary care use. AM is awaiting evidence papers from AstraZeneca on Symbicort, as this is also licensed as a once daily dose as “Symbicort maintenance and reliever therapy”.	Approved for DOT only, prescribed by HEY				
		POB is to discuss & clarify commissioning DOT with the respiratory service manager.	POB to clarify commissioning	POB to ask service manager	POB	03/17	
		Cabozantinib – Prof A Maraveyas Approved subject to NICE. Approved as free of charge (FOC) use, prior to NICE TA due in June/17.	Approved for FOC use	POB to check FOC status	POB	03/17	

2017.02.06	**NICE Guidance**	**NICE Guidance January 2017**					
		NG62 - Cerebral palsy in under 25s: assessment and management | Guidance and guidelines | NICE	Noted - No formulary issues.				02/17
		NG 63 - Antimicrobial stewardship: changing risk-related behaviours in the general population | Guidance and guidelines | NICE	Noted – not for acute hospitals				02/17
		TA427 - Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib | Guidance and guidelines | NICE	Non-formulary	ML to seek Application	ML	03/17	
		TA428 - Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy | Guidance and guidelines | NICE	Non-formulary	ML to seek Application	ML	03/17	
		TA429 - Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation | Guidance and guidelines | NICE	On CDF List only	ML to seek Application	ML	03/17	
		TA430 - Sofosbuvir–velpatasvir for treating chronic hepatitis C | Guidance and guidelines | NICE	Sofosbuvir on formulary but velpatasvir is not	POB to seek Application	POB	03/17	
		TA431 - Mepolizumab for treating severe refractory eosinophilic asthma | Guidance and guidelines | NICE	Approved as above				02/17
		CG62 - Antenatal care for uncomplicated pregnancies (update)	Noted - No formulary issues.				02/17
2017.02.07	**MHRA Drug Safety Update**	**January 2017** Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation.	All noted				02/17

		Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR. Apremilast (Otezla▼): risk of suicidal thoughts and behaviour. Intravenous N-acetylcysteine (NAC) for paracetamol overdose: reminder of authorised dose regimen; possible need for continued treatment with NAC.					
2017.02.08	**Minutes from SMPC**	None					02/17
2017.02.09	**Minutes from HERPC**	None					02/17
2017.02.10	**Correspondence Received**	**Pecfent (Fentanyl Nasal Spray) – Dr L O'Toole** This product was originally requested and approved for Palliative Care only. Dr O'Toole requested that it be available for Oncology patients with Head and Neck Cancers, where other options were unsuitable. This was approved by the committee. **Tiotropium (Braltus) 10microgram Inhalation Powder**- A Cracknell Tiotropium is already on the formulary. As this formulation was cheaper than Spiriva there was no reason to not use it if appropriate for a patient e.g. that was admitted already on it. **Stalevo & generics** Jane Morgan had received feedback from the MHRA. They have received 19 UK ADR reports with the original branded multiple component product Stalevo, of which 8 were "drug ineffective". With Sastravi there was only 1 single report that was "drug ineffective". There were no reports for Stanek. Dr Ming had reported that a small cohort of patients were having adverse effects from the switch over from Stalevo. It was agreed that AM would write to Dr Ming to propose that we continue to use the Sastravi product at HEY, as there were cost savings and there appeared to be no safety concerns raised by the MHRA ADR data. There was further discussion by the committee regarding what	Update formulary to include use for head and neck cancer, initiated by Consultant Oncologist. Braltus approved for use AM to propose to Dr Ming that Sastravi is used instead of Stalevo.	SG to amend formulary & discuss status at next HERPC SG to add to Pharmacy computer & ensure stock available AM to write to Dr Ming.	SG SG AM	03/17 03/17 03/17	

		happened with other branded products - when patients were changed onto a generic version, or were swapped from one generic version to another generic version. It was felt that this warranted greater discussion and should be put on the next agenda.	To be discussed at D&TC next time	SG to add to next agenda .	SG	03/17	
2017.02.11	**Chairs approvals**	**Thalidomide** - **Orofacial Granulomatosis – Dr T Diggory** There was no record on the Pharmacy computer of this being issued. AM to write to Dr Diggory to ask about the patient. POB to check regarding funding. **Intra vesical formalin - intractable haematuria due to radiation cystitis - Mr N Smith** **Xultophy (Insulin degludec & liraglutide) - Diabetes - Dr B Allen** An IFR had been done and approved.	Noted. Noted. Not supplied from Pharmacy. Noted.	AM to write to Dr Diggory. POB to check funding. No Further Action No Further Action.	AM POB	03/17 03/17	 02/17 02/17
2026.12.12	**Issues To Escalate To Operational Quality Committee**	None.					03/17
2026.12.13	**Any Other Business**	None.					03/17
2026.12.15	**Date and Time of Next Meeting**	**Date –** 9/3/17 **Time -** 8.15am-9.30am **Venue –** Board Room, HRI					